Lupin Signs Promotional Agreement with Exeltis on SOLOSEC® (secnidazole) expanding access for Adult Women Suffering with Bacterial Vaginosis and Adults with Trichomoniasis

Mumbai, January 27, 2022: Lupin Pharmaceuticals Inc., (Lupin) and Exeltis USA Inc. announced a promotional agreement for Exeltis to promote SOLOSEC® along with Exeltis’ existing line of Women’s Health products, further enhancing value to OBGYNs and their patients. SOLOSEC® is indicated for the treatment of Bacterial Vaginosis in adult women (a common vaginal infection) and Trichomoniasis in adults (the most common non-viral, curable sexually transmitted infection in the U.S.).1-4

“This partnership will expand the reach of SOLOSEC®, allowing more Healthcare Providers to be aware of the benefits of SOLOSEC®, and increase access for adult women suffering with bacterialvaginosis and adults with trichomoniasis,” said Vinita Gupta, Chief Executive Officer of Lupin “We are extremely excited to partner with Exeltis.” Salustiano Perez, Chief Executive Officer of Exeltis added, “Our team is thrilled to embark on this partnership. The addition of Solosec fits precisely within our current portfolio of products, enhancing our commercial strategy, and offering numerous solutions to our customers and their patients”.